An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir-grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study).
Jean-Pierre BronowickiPatrick MiailhesBertrand HanslikDenis OuzanDominique LarreyGhassan RiachiRégine TruchiVincent JouannaudDan PospaitArmand AbergelXavier CausseStéphanie PerotJérémy SkrzypskiAstrid De HautecloqueAxelle SpampinatoPhilippe MariotPhilippe Sogninull nullPublished in: Health science reports (2022)
Using real-world evidence data on a French population representative of HCV patients, we confirmed the results obtained during EBR/GZR development program.
Keyphrases
- hepatitis c virus
- end stage renal disease
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- systematic review
- cross sectional
- human immunodeficiency virus
- prognostic factors
- peritoneal dialysis
- electronic health record
- hepatitis c virus infection
- machine learning
- liver fibrosis
- antiretroviral therapy
- replacement therapy
- combination therapy
- patient reported